CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 60.21 CNY -1.67%
Market Cap: 6.9B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CanSino Biologics Inc
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Net Issuance of Debt
ÂĄ39.4m
CAGR 3-Years
N/A
CAGR 5-Years
-1%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Issuance of Debt
-ÂĄ19m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Issuance of Debt
ÂĄ163.2m
CAGR 3-Years
N/A
CAGR 5-Years
7%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Issuance of Debt
-ÂĄ16.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Issuance of Debt
ÂĄ404.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Issuance of Debt
ÂĄ208m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
6.9B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
100.07 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Net Issuance of Debt?
Net Issuance of Debt
39.4m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Net Issuance of Debt amounts to 39.4m CNY.

What is CanSino Biologics Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
-1%

Over the last year, the Net Issuance of Debt growth was -97%.

Back to Top